The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 358:1899-1908 May 1, 2008 Number 18
NextNext

Shared Genetic Causes of Cardiac Hypertrophy in Children and Adults
Hiroyuki Morita, M.D., Heidi L. Rehm, Ph.D., Andres Menesses, M.D., Barbara McDonough, R.N., Amy E. Roberts, M.D., Raju Kucherlapati, Ph.D., Jeffrey A. Towbin, M.D., J.G. Seidman, Ph.D., and Christine E. Seidman, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-PowerPoint Slide Set
-Supplementary Material
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
ABSTRACT

Background The childhood onset of idiopathic cardiac hypertrophy that occurs without a family history of cardiomyopathy can portend a poor prognosis. Despite morphologic similarities to genetic cardiomyopathies of adulthood, the contribution of genetics to childhood-onset hypertrophy is unknown.

Methods We assessed the family and medical histories of 84 children (63 boys and 21 girls) with idiopathic cardiac hypertrophy diagnosed before 15 years of age (mean [±SD] age, 6.99±6.12 years). We sequenced eight genes: MYH7, MYBPC3, TNNT2, TNNI3, TPM1, MYL3, MYL2, and ACTC. These genes encode sarcomere proteins that, when mutated, cause adult-onset cardiomyopathies. We also sequenced PRKAG2 and LAMP2, which encode metabolic proteins; mutations in these genes can cause early-onset ventricular hypertrophy.

Results We identified mutations in 25 of 51 affected children without family histories of cardiomyopathy and in 21 of 33 affected children with familial cardiomyopathy. Among 11 of the 25 children with presumed sporadic disease, 4 carried new mutations and 7 inherited the mutations. Mutations occurred predominantly (in >75% of the children) in MYH7 and MYBPC3; significantly more MYBPC3 missense mutations were detected than occur in adult-onset cardiomyopathy (P<0.005). Neither hypertrophic severity nor contractile function correlated with familial or genetic status. Cardiac transplantation and sudden death were more prevalent among mutation-positive than among mutation-negative children; implantable cardioverter–defibrillators were more frequent (P=0.007) in children with family histories that were positive for the mutation.

Conclusions Genetic causes account for about half of presumed sporadic cases and nearly two thirds of familial cases of childhood-onset hypertrophy. Childhood-onset hypertrophy should prompt genetic analyses and family evaluations.


Source Information

From the Department of Genetics, Harvard Medical School (H.M., B.M., R.K., J.G.S., C.E.S.); the Harvard Medical School–Partners HealthCare Center for Genetics and Genomics (H.L.R., A.E.R., R.K., J.G.S.); the Howard Hughes Medical Institute and Brigham and Women's Hospital (B.M., C.E.S.); and the Department of Cardiology, Children's Hospital (A.E.R.) — all in Boston; and the Department of Pediatrics, Baylor College of Medicine, Houston (A.M., J.A.T.).

Drs. J.G. Seidman and C.E. Seidman contributed equally to this article.

This article (10.1056/NEJMoa075463) was published at www.nejm.org on April 9, 2008.

Address reprint requests to Dr. Christine Seidman at the Department of Genetics, Harvard Medical School, Rm. 256 NRB, 77 Ave. Louis Pasteur, Boston, MA 02115, or at cseidman{at}genetics.med.harvard.edu.

Full Text of this Article


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.